PTGS2 and cancer: Our results here propose that Egr1 is one of the Mapk3/1 regulated transcription factors that transactivates its target genes involved in follicular rupture such as Ptgs2. Finally, several Map2k-inhibitors are under advanced clinical trial for anti-cancer therapy.